News about Market

GSK Enters Agreement to Acquire Nuvalent

GSK has agreed to acquire Nuvalent in a multi-product oncology deal that strengthens its lung cancer portfolio with two late-stage, potential best-in-class therapies—zidesamtinib and neladalkib—for non-small cell lung cancer.

Market | 10/06/2026 | By News Bureau |  316

Syntax Bio and Mayo Clinic Partner on Type 1 Diabetes Cell Therapy

Syntax Bio and Mayo Clinic have partnered to accelerate the development of stem cell-derived pancreatic cell therapies for Type 1 Diabetes (T1D). The collaboration aims to advance regenerative medicine approaches that could restore insulin-producing cells.

Market | 10/06/2026 | By News Bureau |  157

Wegovy Pill Prescriptions Surpass 3 Million as Novo Nordisk Presents New ADA 2026 Data

Novo Nordisk announced that Wegovy pill prescriptions have surpassed 3 million since launch, marking one of the largest US pharmaceutical launches by volume. Most prescriptions are from people new to GLP-1 therapy, expanding access to obesity treatment, while new clinical analyses are being presented at ADA 2026.

Market | 10/06/2026 | By News Bureau |  887

Incyte to Acquire Vega Therapeutics, Expanding Hematology Portfolio

Incyte has agreed to acquire Vega Therapeutics, expanding its hematology portfolio into bleeding disorders with the addition of VGA039, a phase 3 investigational monoclonal antibody for von Willebrand disease. The deal includes USD 1.25 billion upfront and up to USD 750 million in additional payments upon achievement of sales milestones.

Market | 09/06/2026 | By News Bureau |  177

Lupin Partners with ERN to Launch Luforbec in Spain

Lupin has partnered with ERN to launch Luforbec (beclometasone/formoterol) pMDI in Spain, combining Lupin’s respiratory expertise and advanced inhaler manufacturing capabilities with ERN’s strong market presence to expand access to high-quality respiratory care for patients across the country.

Market | 08/06/2026 | By News Bureau |  145

GVRP and Steps Biosciences Launch Advanced Formulations Research Centre in Bengaluru

GVRP and Steps Biosciences have inaugurated the GVRP StepsBio Research Centre (GSRC) at Bengaluru’s Lifescapes life sciences cluster, strengthening India’s pharmaceutical innovation ecosystem with advanced facilities for complex formulations, sterile injectables, analytical testing and AI-enabled drug development.

Market | 06/06/2026 | By News Bureau |  185

Teva Pharma Launches AHZANTIVE Biosimilar to Eylea in Europe

Teva has launched AHZANTIVE (aflibercept), an EMA-approved biosimilar to Eylea, across Europe. Demonstrating comparable efficacy, safety, and immunogenicity to the reference product, the launch expands Teva’s biosimilars and ophthalmology portfolio while supporting its long-term Pivot to Growth strategy.

Market | 06/06/2026 | By News Bureau |  175

Gilead and Lakefront Complete Acquisition of Ouro Medicines

Gilead Sciences and Lakefront have completed the acquisition of Ouro Medicines, expanding their inflammation and autoimmune disease pipeline. The companies will jointly advance gamgertamig, a potential first-in-class and best-in-class T-cell engager therapy designed to address unmet needs in autoimmune disorders.

Market | 05/06/2026 | By News Bureau |  117

Glenmark Launches Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials

Glenmark Pharmaceuticals Inc., USA has launched Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), a bioequivalent and therapeutically equivalent generic version of Vimpat Injection.

Market | 05/06/2026 | By News Bureau |  114

Novo Nordisk Launches Wegovy Weight-Loss Pill in UAE, First Market Outside the US

UAE becomes first country outside the United States to offer the oral semaglutide treatment for obesity, marking a key step in Novo Nordisk’s global expansion plans.

Market | 04/06/2026 | By News Bureau |  152